State Of Wisconsin Investment Board Argenx Se Transaction History

State Of Wisconsin Investment Board

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $105,634 - $156,850	286 Added 2.47%	11,874 $5.84 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $993,665 - $1.2 Million	2,973 Added 34.51%	11,588 $4.32 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $1.41 Million - $1.65 Million	4,108 Added 91.15%	8,615 $3.26 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $257,400 - $296,812	750 Added 19.96%	4,507 $1.59 Million
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $765,385 - $1.06 Million	-3,008 Reduced 44.46%	3,757 $1.19 Million
Q4 2021 Feb 11, 2022	BUY	$272.01 - $353.03 $901,169 - $1.17 Million	3,313 Added 95.97%	6,765 $2.37 Million
Q2 2021 Aug 12, 2021	BUY	$257.11 - $319.92 $887,543 - $1.1 Million	3,452 New	3,452 $1.04 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.